MRK
Merck & Co., Inc.
USNYSE: MRK
MRK
Merck & Co., Inc.
USNYSE: MRK
Healthcare
Drug Manufacturers - GeneralUS

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

$89.55

0%
$0
Grades
A+
Great stock across the board.
Excellent quality, with strong balance sheet and profitability. A fantastic company.
Excellent dividend and business growth. Expect long-term dividend growth and capital appreciation.
The stock appears undervalued by most metrics. A great time to buy.
Market Cap
$226B
Mega-Cap
EPS (TTM)
$4.80
Dividend Yield
3.14%
Great Yield
Dividend Streak
13 years
Since 2012
Payout Ratio
67.5%
OK Payout
Dividend Growth
6.8%
CAGR - 5Y
Revenue/ share$25.25
FCF/ share$7.12
Earnings Yield7.52%
Gross Margin80.85%
Operating Margin35.36%
ROE39.18%
Cash$13.2B
Net Debt$23.9B
Debt to Equity0.80
PE13.29
EV/Sales3.90
Beta0.36